Intravenous Administration

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer.

Published results showed oral antibiotics may be noninferior to IV antibiotics with respect to number of surgical interventions required within 1 year for patients with fracture-related infections.

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press release from Novartis.

AUSTIN, Texas — Treatment with IV ketamine for pediatric refractory headache resulted in a 50% reduction in pain at discharge, with nearly two-thirds of patients not requiring rescue care within 1 month, according to a poster presentation.

For individuals diagnosed with treatment-resistant depression, response and remission rates for IV ketamine and intranasal esketamine were similar, but remission time was quicker with the former compared with the latter.

For patients with a history of coronary artery disease or coronary stents who undergo total joint arthroplasty, use of topical and intravenous tranexamic acid is safe, according to published results.

With associated congruent reinfection and reoperation rates, oral antibiotics are noninferior to IV antibiotics for fracture-related infections, according to results presented at the Orthopaedic Trauma Association Annual Meeting.

Use of IV ibuprofen was successful in managing pain and prolonging time to first narcotic administration in orthopedic trauma patients, according to published results.

GRAND RAPIDS, Mich. — As infusion centers have grown in complexity throughout the years, so too has the patient experience in these suites, with individuals often asked to take on a greater understanding of the clinical and financial impacts of their treatment, according to a presenter at the National Organization of Rheumatology Managers Annual Conference.